Document is current
Any future updates will be listed below
-
Authors
To, Briana
Prasath, Vishnu
Veney, Deloris
Rolfo, Christian
Adalsteinsson, Viktor
Carson, William E. III
Wesolowski, Robert
Stover, Daniel
Quiroga, Dionisia https://orcid.org/0000-0003-3388-7069
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA016058)
National Cancer Institute (P30 CA016058)
National Cancer Institute (P30 CA016058)
National Cancer Institute (P30 CA016058)
National Cancer Institute (P30 CA016058)
National Cancer Institute (P30 CA016058)
National Cancer Institute (UH3CA239105)
National Cancer Institute (P30 CA016058)
- License Information
-
More Information
Article History
Received: 27 July 2025
Accepted: 6 April 2026
First Online: 16 April 2026
Competing interests
: Christian Rolfo : Advisory Board/Speaker: AstraZeneca, Daiichi Sankyo, Regeneron and Novocure; Bristol-Myers Squibb, Novartis, Guardant Health, COR2ED, Bayer, Boehringer Ingelheim, AbbVie, Invitae, Janssen, EMD Serono, OneCell Dx, Neogenomics, Touch Oncology, Pfizer. Research Grants: Astra Zeneca, Thermo Fisher, Oncohost, Lung Cancer Research Foundation, National Foundation for Cancer Research, and U54 (National Institute of Health), Research collaborations: GuardantHealth, Foundation Medicine, Roche Diagnostics, EMD Serono, Janssen Pharmaceutical (LUNGMAP S1900J trial). Scientific advisory board member of Imagene AI. Daniel Stover: Advisory Board Natera, Guardant. Research funding (in kind to institution): NeoGenomics, Foundation Medicine. Viktor Adalsteinsson: royalties paid and research funding from Exact Sciences; co-founder and advisor of Amplifyer Bio. All other authors in this manuscript declare no competing financial or non-financial interests.
